Although TGF‐beta activates a wide range of tumour stroma cell types (Pickup et al., 2013), CAFs are the main contributors to the association of stromal TGF‐beta‐driven programmes with poor clinical outcome in CRC, suggesting a predominant role of TGF‐beta‐activated CAFs during progression to metastasis (Calon et al., 2015). Here, TGFB1 is linked to neoplasm.